Background: Lymphoma-associated hemophagocytic syndrome (LAHS) is a highly fatal immune disorder. Poor prognosis is partly attributed to under diagnosis or delayed diagnosis. Aim: Early identification of LAHS patients based on the laboratory findings could improve the outcomes. Design: Retrospective observational cross-sectional study. Methods: From January 2011 to June 2016, 282 adult patients with hemophagocytosis in bone marrow were enrolled, and 114 hemophagocytic lymphohistiocytosis (HLH) patients with definite underlying cause were finally included for analysis. The HLH patients were further divided into LAHS (76 out of 114) and non-malignancy-associated HLH (38 out of 114) groups. Results: Compared to non-malignancy-associated HLH, LAHS patients had significantly elevated lactate dehydrogenase (LDH) levels, increased thickness of spleen, higher proportion of patients with lymphadenopathy and significantly decreased peripheral blood cell count. In multivariate logistic regression model analysis, thickness of spleen !5 cm (OR ¼ 17.9, 95%CI 1.35-236.6; P ¼ 0.028), IL-6 level !55.1 pg/ml (OR ¼ 12.01, 95%CI 1.03-138.9; P ¼ 0.047) and IL-10 level !425.9 pg/ml (OR ¼ 51.18, 95%CI 2.53-1035.1; P ¼ 0.010) were independent predictors of LAHS diagnosis. Based on the regression parameters, we established a diagnostic index with weighted risk scores of 1 assigned to thickness of spleen and IL-6 level respectively, and a score of 3 assigned to IL-10 level. A diagnostic index ! 2 points had the best AUC value (0.889) with 84.2% of sensitivity and 93.7% of specificity for predicting LAHS. Conclusions: LAHS can be considered when HLH patients have a diagnostic index !2 points, so actively looking for evidence of lymphoma and effective chemotherapy may be necessary.
Introduction
Hemophagocytic syndrome, also known as hemophagocytic lymphohistiocytosis (HLH), is a rare, life-threatening immune disorder; it's characterized by high fever, pancytopenia, hepatosplenomegaly, liver dysfunction, coagulopathy, elevated ferritin levels, and the increased proliferation and activation of benign macrophages with hemophagocytosis in bone marrow or other organs. The disease can be divided into primary (underlying genetic basis) and secondary forms. Primary HLH have a family history of HLH or identifiable genetic defects in genes involved in lymphocyte cytotoxicity, including PRF1, 4, 5 RAB27A, 6 LYST 7 and AP3B1. 8 Secondary HLH affects a wide age range, especially older children and adults. 9 It can be triggered by various underlying conditions, mainly infections, for instance Epstein-Barr virus (EBV) infection, underlying rheumatologic disorders, such as systemic lupus erythematosus, or malignancies especially lymphoma. HLH, especially lymphoma-associated hemophagocytic syndrome (LAHS) used to be a fatal disease. In general, the patients would experience a rapid and fatal course without timely and effective treatment due to lack of identification of underlying cause of HLH. Therefore, early diagnosis of the underlying condition, and especially of lymphoma, leads to better outcomes. However, the diagnosis of LAHS is often difficult because of the frequent lack of lymphadenopathy or mass formation amenable to biopsy, which results in the development of progressive disease with an unfavorable prognosis. The identification of clinical and laboratory features specific to LAHS in adults may allow for early detection and intervention with improved outcomes.
In the case of LAHS, possible mechanisms of pathogenesis include extreme inflammation, loss of immune homeostasis because of chemotherapy or infection and persistent antigen stimulation by tumor cells, which leads to over secretion of cytokines, including interleukin-6 (IL-6), IL-10, interferon-c (IFN-c) and so on. 10 Tang et al. 11 have demonstrated that a specific T-helper cell type 1 (Th1) and 2 (Th2) cytokine pattern could be used to early diagnosis HLH in children and highly increased IL-10 at diagnosis was an independent prognostic factor of early death in children HLH. 12 Therefore, we highly suspect that serum Th1/Th2 cytokines may play an important role in the pathogenesis of LAHS and could be used as early predictors for LAHS diagnosis. Here, we retrospectively analyzed a series of 114 Chinese adult with secondary HLH and examined whether regular laboratory parameters and serum Th1/Th2 cytokines on admission could be used to differentiate LAHS from other reactive HLH.
Methods

Patients and data collection
From January 2011 to June 2016, 282 adult patients (age !18 -years) with hemophagocytosis in bone marrow examination in the First Affiliated Hospital, College of Medicine, Zhejiang University were retrospectively analyzed. The ethics committee approved this study. All patients provided written informed consent to participate in the study. HLH was diagnosed according to HLH-2004 protocol of the International Histiocyte Society. 13 The HLH-2004 study required patients to have the following five of eight features: (1) prolonged fever (a temperature >38.5 C for at least 7 days), (2) splenomegaly (the costal margin exceeded 3 cm), (3) hemophagocytosis, (4) cytopenia involving at least two blood cell lineages: hemoglobin <90 g/l, platelet count <100 Â 10 9 /l or neutrophil count <1 Â 10 9 /l, (5) hypofibrinogenemia or hypertriglyceridemia: fasting triglycerides >3 mmol/l or fibrinogen <1.5 g/l, (6) hyperferritinemia: total serum ferritin levels >500 lg/l, (7) low or absent activity in NK cells and (8) elevated levels of soluble CD25 concentration. According to HLH-2004 protocol, 222 HLH patients were included for analysis. All relevant demographic characteristics, clinical features and laboratory findings at the time of HLH diagnosis (on admission, pre-treatment) were gathered from medical records. Follow-up was performed by reviewing medical records or making phone calls. Overall survival (OS) was measured as the time from HLH diagnosis to the date of death from any cause or the last follow-up. Patients died within 30 days after diagnosis were defined as early death.
Study design
Information related to treatment and the underlying cause of HLH was thoroughly reviewed. The diagnosis of LAHS was made on the basis of lymph node biopsy, spleen biopsy or bone marrow biopsy. In non-malignancy-associated HLH, the cause for HLH was determined as follows. When patients presented as active viral, bacterial or fungal infections that were microbiologically or radiologically demonstrated, they were designated as infectionassociated HLH. Cases clinically suspicious of infection were also designated as infection-associated HLH even though pathogens were not identified. Patients satisfying the American College of Rheumatology diagnostic criteria for autoimmune disease without any evidence of other disease-causing HLH were designated as the autoimmune disease-associated HLH. According to the underlying cause for each case of HLH, patients were classified into dichotomous groups of lymphoma-associated and nonmalignancy-associated HLH. Clinical and laboratory features as well as survival outcomes were compared between these two types of HLH. As a result, a total of 114 patients with definite cause of HLH were included for analysis, another 108 patients with unknown origin of HLH were excluded.
Treatment regimens
All HLH patients received treatment according to the international guidelines for the treatment of HLH-2004. 13 Patients in the non-malignancy-associated HLH group were treated with the following treatment regimens: corticosteroid þ intravenous immunoglobulins (IVIG) (7.9%), corticosteroid þ IVIG þ etoposide (81.6%) or corticosteroid þ IVIG þ etoposide þ cyclosporine (10.5%). Patients with LAHS received CHOP-based chemotherapy regimens: EPOCH (78.9%), E-CHOP (3.9%), R-CHOP (7.8%) or Hyper-CVAD (9.2%) (etoposide or rituximab combined with glucocorticoid, vincristine, cyclophosphamide and adriamycin). EBV-related HLH patients were treated with ganciclovir. Patients with sepsis were administered sensitive antibiotics. Patients with liver lesions were given drugs for protecting liver function. Patients with anemia or coagulopathy were transfused with red cells, fibrinogen or fresh frozen plasma.
Cytokine determination
Serum Th1/Th2 cytokine including IL-2, IL-4, IL-6 IL-10, IL-17A, IFN-c and tumor necrosis factor-a (TNF-a) levels were quantitatively determined by flow cytometry. The patients' cytokines data at the time of diagnosis were collected.
Statistical analysis
Continuous variables were expressed as means 6 SD. Continuous and categorical variables of LAHS and nonmalignancy-associated HLH groups were compared using a two-tailed Student's t-test and chi-square test, respectively. The correlation between the patients' clinical parameters and LAHS was assessed using univariate logistic regression analyses. ROC curve analysis was performed to determine accuracy and optimal cut-off values of patients' clinical parameters for predicting LAHS. We categorized laboratory variables according to the cutoff values, and included these categorized variables for further multivariate stepwise logistic regression analyses if the corresponding continuous variables were significantly associated with LAHS in univariate analyses. Then we constructed the diagnostic index on the basis of the independent factors included in the final multivariable logistic regression model. We assigned a weighted risk score to each factor based on the regression parameters from the logistic regression analysis. The predictive score was then defined as the sum of single-risk parameters. OS curves were constructed using the KaplanMeier method and were compared with the log-rank test. Differences between the results of comparative tests were considered significant if the two-sided P-values was <0.05. All statistical analyses were performed using STATA version 12.0 (StataCorp, College Station, TX, USA).
Results
Patient characteristics and survival analysis
This study included a total of 114 adult HLH patients with definite underlying cause. Seventy-six of these patients were confirmed to have LAHS, of which the median age ranged from 18 to 84 years, with 72.4% male participants. Thirty-eight of the 114 enrolled patients were confirmed to have non-malignancyassociated HLH, of which the median age ranged from 18 to 86 years, with 50% male participants. The underlying diseases of these two groups are summarized in Table 1 . After initial treatment, there were 68.5% (24/35) of patients in nonmalignancy-associated HLH group and 26.2% (16/61) of patients in LAHS group achieving complete remission (CR), and the remaining patients who failed to achieve remission eventually died. The survival follow-up data were obtained from 96 patients. Kaplan-Meier survival analysis showed that patients with LAHS had shorter OS compared with those with nonmalignancy-associated HLH (Table 1) (P < 0.01). The early death rate of LAHS group (49.2%) were significantly higher than that of non-malignancy-associated HLH group (20%) (P < 0.01).
Comparison of patients' clinical and laboratory findings between non-malignancy-associated HLH and LAHS groups
Comparisons of clinical parameters at diagnosis between nonmalignancy-associated HLH and LAHS groups were shown in Table 2 . Three parameters were significantly elevated in LAHS than those in non-malignancy-associated HLH: lactate dehydrogenase (LDH) levels, thickness of spleen (by ultrasonic examination) and proportion of patients with number of enlarged lymph nodes more than 3. Five parameters were significantly decreased in LAHS group: white blood cell counts, neutrophil counts, lymphocyte counts, hemoglobin levels and platelet counts. No significant difference was found in the other laboratory parameters between non-malignancy-associated HLH and LAHS groups.
Univariate logistic regression analysis and receiver operating characteristic (ROC) analysis of patients' clinical parameters in predicting LAHS Univariate analysis of patients' clinical parameters for diagnosis of LAHS in logistic regression model was performed ( Table 3) . The variables significantly associated with LAHS were white blood cell count, neutrophil count, lymphocyte count, hemoglobin level, platelet count, LDH level, the thickness of spleen, IL-6 level and IL-10 level. ROC analysis was performed to determine the accuracy and optimal cut-off values of the above clinical parameters which were significantly associated with LAHS in univariate analysis. Among the variables, elevated thickness of spleen with a cut-off value of !5 cm, increased IL-6 level with a cut-off value of !55.1 pg/ml and increased IL-10 level with a cutoff value of !425.9 pg/ml showed higher diagnostic values with area under the curve (AUC) values more than 0.7 in predicting LAHS.
Multivariate stepwise logistic regression analysis of patients' clinical parameters for LAHS diagnosis and diagnostic index establishment
To determine independent predictors for diagnosis of LAHS, multivariate stepwise logistic regression was used for the nine significant variables identified by univariate analysis. According to the cut-off values, patients were classified into two categories. Splenomegaly (thickness of spleen ! 5 cm; OR ¼ 17.9, 95%CI 1.35-236.6; P ¼ 0.028), increased IL-6 level (!55.1 pg/ml; OR ¼ 12.01, 95%CI 1.03-138.9; P ¼ 0.047) and increased IL-10 level (!425.9 pg/ml; OR ¼ 51.18, 95%CI 2.53-1035.1; P ¼ 0.010) were found to be significantly independent predictors of LAHS diagnosis (Table 4) . The final multivariable model constituted the basis for diagnostic index of LAHS. On the basis of the regression coefficient and odds ratios, we defined the following criteria to establish individual weighted risk scores of the three independent factors. The factors of thickness of spleen and IL-6 level should receive identical scores due to similar regression coefficients and odds ratios, accordingly, these two factors should receive the lowest score; the weighted risk score of IL-10 level should be at least triple the weighted risk score of the above two factors based on odds ratios values. Thus, weighted risk scores of 1 were assigned to thickness of spleen and IL-6 level respectively, and a score of 3 was assigned to IL-10 level. The diagnostic index for LAHS resulted in total risk scores between 0 and 5. ROC analysis showed that a diagnostic index greater than or equal to 2 points had the best AUC value (0.889) with 84.2% of sensitivity and 93.7% of specificity for predicting LAHS (Table 5) .
Discussion
Secondary HLH presents in a number of different clinical contexts with various etiologic associations, such as infection, malignancy or autoimmune disorders. In a large, multicenter study on 162 adult patients with HLH, hematologic malignancies, especially non-Hodgkin lymphomas (NHL), were the main trigger of HLH, accounting for 56% of cases.
14 Patients with malignancies-associated HLH had a higher early mortality than those with underlying infection. 15 A Japanese survey 15 also revealed that LAHS was a major subtype in adult-onset HLH cases, accounting for 43% of HLH patients older than 15 years of age and for 67% of patients older than 60 years of age. Approximately 32% of patients with LAHS were associated with nature killer/T (NK/T) cell lymphoma mainly presenting in peripheral T-cell lymphoma (PTCL) (12%) and extranodal NK/T-cell lymphoma (ENKL) (11%), and approximately 64% with B-cell lymphoma mainly presenting in diffuse large B-cell lymphoma (DLBCL) (15%) and intravascular large B-cell lymphoma (IVLBCL) (14%). The study also showed LAHS had a poorer outcome that 5-year OS rates were only 12.2% and 48.2% for NK/T cell lymphoma-associated HLH and B-cell lymphoma-associated HLH respectively, significantly lower than infection-associated HLH (89%) and autoimmune-associated HLH (89.6%). In this study, we presented 114 secondary HLH cases diagnosed at a single institution. Most of LAHS patients (77.6%) were associated with NK/T cell lymphoma, of which the major histologic subtypes were ENKL (27.6%) and PTCL (13.2%). Our study also showed that even with the standard chemotherapy, LAHS patients had the worse prognosis with significantly higher early death rate (49.2%) and shorter median OS (only 2 months) when compared with non-malignancy-associated HLH. LAHS is a rapidly progressing and life-threatening disease. Misdiagnosis or delayed diagnosis of LAHS often occurs because of the lack of absence of apparent lymph node enlargement or mass formation amenable to biopsy, which further contributing the progression of the disease with an unfavorable prognosis. Therefore, in this study we investigated the clinical and laboratory characteristics of LAHS from other non-malignancyassociated HLH and obtained some clinical experiences to make early diagnosis. Although some clinical features of LAHS have been reported, [16] [17] [18] there is no consensus about the clinical features and predictive factors for LAHS diagnosis. Jia et al. 16 reviewed the clinical records of 202 patients with ENKL and compared the clinical characteristics of ENKL patients with and without HLH. A multivariate logistic regression analysis showed that younger age, bone marrow involvement and reduced serum albumin were independent risk factors for developing HLH in patients with ENKL. Li et al. 17 also retrospectively analyzed 21 ENKLassociated HLH patients, and found bone marrow involvement, hepatosplenomegaly and elevated LDH level were risk factors for ENKL-associated HLH. Another study 18 retrospectively analyzed the clinical characteristics and laboratory findings of 16 LAHS patients from 69 adult HLH patients. The results showed that the percentages of patients with fibrinogen <1.5 g/l, platelet count <40 Â 10 9 /l and LDH !1000 u/l in the LAHS group were significantly higher than those in non-lymphoma-associated patients. However, univariate and multivariate logistic regression analyses were not performed in their study. In our study, we showed similar results that LDH levels, thickness of spleen and the proportion of patients with lymphadenopathy were significantly elevated in LAHS than those in non-malignancyassociated HLH, while peripheral blood cell count were significantly decreased. But when conducting the multivariate logistic regression analysis, we found among above variables, only splenomegaly with thickness of spleen !5 cm was an independent factor for predicting LAHS. Surprisingly, cytokines IL-6 and IL-10 levels were shown to have important diagnostic value as independent predictors in LAHS. Hypercytokinemia is a major pathologic feature of HLH, caused by hyperactivation and hyperproliferation of cytotoxic T lymphocytes and macrophages. High levels of cytokines and organ infiltration are associated with various clinical features of HLH. 19, 20 Some studies have shown that the patients with active HLH had elevated Th1/Th2 cytokines including IL-10, IFN-c and IL-6, while TNF, IL-4 and IL-2 were at normal range or slightly elevated. 11, 20, 21 Other reports also found that TNF-a was moderately elevated in most HLH cases, but the level was not as high as IFN-c and IL-10. 22 High IFN-c and IL-10 levels were reported to be associated with early death in HLH, 19, 23 and IFN-c and IL-18 were considered to play a pivotal role in the development of HLH and thought to be sensitive indicators of disease activity. [24] [25] [26] In our study, patients in two subgroups have cytokine profiles similar to the specific cytokine pattern found in previous reports: significantly elevated IL6, IL-10 and IFN-c levels with moderately increased IL-17A level and normal IL-2, IL-4 and TNF-a levels when compared with normal ranges. Although hypercytokinemia in HLH has been noted, a clinically useful cytokine profile specific to LAHS has not been established. Our result showed that increased IL-6 and IL-10 levels were independent factors for predicting LAHS, particularly IL-10 level has more important diagnostic value with odds ratios triple that of IL-6. Indeed, it has been shown that serum levels of IL-6 and IL-10 are elevated in B-cell NHL, and elevated levels are associated with more adverse disease features and inferior prognosis. 27, 28 Several studies have provided evidence for the role of IL-10 in the pathogenesis of malignant B-cell neoplasms, including activating the JAK2 pathway 28 and inducing the development of immunosuppressive CD14 þ HLA-DR low/À monocytes. 29 A recent study also reported that in human NHL, IL-6 and IL-10 secreted by tumor-associated macrophages up-regulated the immunosuppressive B7-H4 molecule, thereby inhibiting host anti-tumor immunity to NHL and resulting in immune evasion of lymphoma cells. 30 Thus, IL-6 and IL-10 are also presumed to play an important role in the pathogenesis of LAHS and increased IL-6 and IL-10 levels could be used to differentiate LAHS from other reactive HLH.
Another important finding in this study was the diagnostic index for LAHS depending on the regression parameters of thickness of spleen, IL-6 level and IL-10 level. As shown in Table 5 , patients can be categorized into six groups according to different predictive scores. Patients with diagnostic index more than or equal to 2 points had higher probabilities to belong to lymphoma-derived HLH. Thus, we suggest that early diagnosis by biopsy and systemic treatment should be performed as soon as possible in HLH patients with diagnostic index over two points regardless of whether or not all diagnostic criteria are fulfilled.
Our study is a retrospective study with small samples, therefore, the results require further verification. In future, largerscale and more standard investigations are needed to validate our diagnostic model and find more meaningful clinical parameters to help diagnosis LAHS.
Conclusions
The symptoms of LAHS patients can be easily confused with other HLH, which leads to misdiagnosis. Splenomegaly (thickness of spleen ! 5 cm), highly increased IL-6 level (!55.1 pg/ml) and highly elevated IL-10 level (!425.9 pg/ml) at diagnosis are independent factors for predicting LAHS. Patients with LAHS could be identified when HLH patients have a diagnostic index !2 points. These findings may help guide to make early diagnosis for LAHS using various tests, such as PET/CT scanning, bone marrow tissue immunohistochemical staining, TCR/ IgH gene rearrangement analysis, and multiple tissue biopsies and provide better treatment decision for this disease for avoiding insufficient therapy.
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